Breaking News

WuXi PharmaTech Site Passes Inspection

SynTheAll facility gets no 483s

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

WuXi PharmaTech has completed a general GMP and Pre-Approval Inspection (PAI) from the FDA for the manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA). No Form 483 was issued. STA has a manufacturing pipeline of small molecule APIs and advanced intermediates for global clients through its integrated platform, which extends from process research and research manufacturing to commercial manufacturing. The inspection outcome confirms STA&...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters